Phase II Trial of Docetaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer: A Japanese Cooperative Study

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1649-1655

  Kunitoh, Hideo ^a   Watanabe, Koshiro ^b   Onoshi, Taisuke ^b   Furuse, Kiyoyuki ^b   Niitani, Hisanobu ^b   Taguchi, Tetsuo ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EDEMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0029913666     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1649     Document Type: Article

References (31)

1. Colin M, Guenard D, Gueritte-Voegelein F: Process for preparing derivatives of baccatin III and of 10-deacetyl baccatin III. Washington, DC, US Patent Office, US Patent 4924012; granted May 8, 1990
2. Denis JN, Correa A, Greene AE: An improved synthesis of the Taxol side chain and of RP56976. J Org Chem 55:1957-1959, 1990
3. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
4. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
5. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
6. Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): A a semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
7. Lavelle F, Fizames C, Gueritte-Voegelein F: Experimental properties of RP 56976, a Taxol derivative. Proc Am Assoc Cancer Res 30:566, 1989 (abstr 2254)
8. Riou JF, Naudin A, Lavelle F: Cellular activities of Taxotere. Proc Am Assoc Cancer Res 33:525, 1992 (abstr 3140)
9. Aapro M, Braakhuis B, Dietel M: Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc Am Assoc Cancer Res 33:516, 1992 (abstr)
10. Bissery MC, Bayssas M, Lavelle F: Preclinical evaluation of intravenous Taxotere (RP 56976, NSC 628503) a Taxol analogue. Proc Am Assoc Cancer Res 31:417, 1990 (abstr 2475)
11. Bissery MC, Guenard D, Gueritte-Voegelein F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
12. Harrison SD, Dykes DJ, Shepherd RV. Response of human tumor xenografts to Taxotere. Proc Am Assoc Cancer Res 33:526, 1992 (abstr 3144)
13. Bissery MC, Vrignaud P, Bayssas M: In vitro evaluation of Taxotere (RP 56976, NSC 628503) in combination with cisplatin, doxorubicin, or vincristine. Proc Am Assoc Cancer Res 33:443, 1992 (abstr 2645)
14. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
15. Schrijvers D, Wanders J, Dirix L, et al: Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610-611, 1993
16. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1788, 1992
17. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
18. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70:384-387, 1994
19. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
20. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
21. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
22. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
23. Taguchi T, Furuse H, Niitani H, et al: Phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug. Jpn J Cancer Chemother 21:1997-2005, 1994 (in Japanese)
24. Zubrod CG, Schneiderman M, Frei E, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphamide. J Chronic Dis 11:7-33, 1960
25. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
26. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130, 1993
27. Yokoyama A, Kurita Y, Watanabe K, et al: Early phase II clinical study of RP 56976 (docetaxel) in patients with primary pulmonary cancer. Jpn J Cancer Chemother 21:2609-2616, 1994 (in Japanese)
28. Kudo S, Hino M, Fujita A, et al: Late phase II clinical study of RP 56976 in patients with non-small cell lung cancer. Jpn J Cancer Chemother 21:2617-2623, 1994 (in Japanese)
29. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
30. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
31. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992